• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Parexel Hires Former FDA, MHRA Regulators

Parexel Hires Former FDA, MHRA Regulators

June 22, 2010
CenterWatch Staff

Parexel Consulting, a business unit of Parexel International, has appointed former regulators Toby Silverman, M.D. and Keith Watson, Ph.D. as principal consultants.

These appointments further expand Parexel Consulting’s global team of regulatory and product development experts to address a growing need among its clients to support accelerated approvals of innovative biotechnology and blood product platforms.

Dr. Silverman served at the U.S. Food and Drug Administration’s  Center for Biologics Evaluation and Research (CBER) for 20 years and was most recently senior advisor in the Office of Blood Research and Review.  Dr. Silverman was responsible for key CBER initiatives related to biologic development, pharmacovigilance and hemovigilance. Dr. Silverman was also formerly branch chief of the Clinical Review Branch in the Division of Hematology at FDA.

Dr. Watson joins Parexel from The Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, where he was engaged with key biotechnology advisory groups in Europe, including the Biologicals and Vaccines Expert Advisory Group, Biologics Working Party and the Committee for Medicinal Products for Human Use. Previously, Dr. Watson held senior level positions within the biopharmaceutical industry, which were focused on biologics manufacturing and quality as well as monoclonal antibody technologies.

“We expect Dr. Silverman and Dr. Watson to provide valuable assistance to our clients’ development programs. They will support our clients in navigating challenging global regulatory environments and creating new regulatory pathways for innovative products that address unmet medical needs” said Paul Bridges, Ph.D., vice president, Parexel Consulting.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing